Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

GABA and glutamate systems as therapeutic targets in depression and mood disorders.

Kendell SF, Krystal JH, Sanacora G.

Expert Opin Ther Targets. 2005 Feb;9(1):153-68. Review.

PMID:
15757488
2.

GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action.

Sanacora G, Saricicek A.

CNS Neurol Disord Drug Targets. 2007 Apr;6(2):127-40. Review.

PMID:
17430150
3.

Metabotropic glutamate receptors in the control of mood disorders.

Witkin JM, Marek GJ, Johnson BG, Schoepp DD.

CNS Neurol Disord Drug Targets. 2007 Apr;6(2):87-100. Review.

PMID:
17430147
4.

Trial watch: phase II boost for glutamate-targeted antidepressants.

Flight MH.

Nat Rev Drug Discov. 2013 Dec;12(12):897. doi: 10.1038/nrd4178. No abstract available.

PMID:
24287771
5.

Preclinical models: status of basic research in depression.

Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK, Hen R, Koester S, Lederhendler I, Meaney M, Robbins T, Winsky L, Zalcman S.

Biol Psychiatry. 2002 Sep 15;52(6):503-28. Review.

PMID:
12361666
6.

Clinical studies implementing glutamate neurotransmission in mood disorders.

Sanacora G, Rothman DL, Mason G, Krystal JH.

Ann N Y Acad Sci. 2003 Nov;1003:292-308. Review.

PMID:
14684453
7.
8.

Dysfunctional hippocampal activity affects emotion and cognition in mood disorders.

Femenía T, Gómez-Galán M, Lindskog M, Magara S.

Brain Res. 2012 Oct 2;1476:58-70. doi: 10.1016/j.brainres.2012.03.053. Epub 2012 Apr 5. Review.

PMID:
22541166
9.

GABAergic functions and depression: from classical therapies to herbal medicine.

Leung JW, Xue H.

Curr Drug Targets CNS Neurol Disord. 2003 Dec;2(6):363-74. Review.

PMID:
14683464
10.

Glutamate- and GABA-based CNS therapeutics.

Foster AC, Kemp JA.

Curr Opin Pharmacol. 2006 Feb;6(1):7-17. Epub 2005 Dec 22. Review.

PMID:
16377242
11.

GABA and mood disorders: a brief review and hypothesis.

Petty F.

J Affect Disord. 1995 Aug 18;34(4):275-81. Review.

PMID:
8550953
12.

Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.

Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF.

Mol Psychiatry. 2002;7 Suppl 1:S71-80. Review.

13.

[The role of zinc in the pathogenesis and treatment of affective disorders].

Siwek MS, Wróbel A, Dudek D, Nowak G, Zieba A.

Psychiatr Pol. 2005 Sep-Oct;39(5):899-909. Review. Polish.

PMID:
16358590
14.

GABA function in mood disorders: an update and critical review.

Shiah IS, Yatham LN.

Life Sci. 1998;63(15):1289-303. Review.

PMID:
9768867
15.

Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders.

Chang L, Cloak CC, Ernst T.

J Clin Psychiatry. 2003;64 Suppl 3:7-14. Review.

16.

Therapeutic potential of novel glutamate receptor antagonists in migraine.

Andreou AP, Goadsby PJ.

Expert Opin Investig Drugs. 2009 Jun;18(6):789-803. doi: 10.1517/13543780902913792 . Review.

PMID:
19426123
17.

The missing link between clinical endpoints and drug targets in depression.

Della Pasqua O, Santen GW, Danhof M.

Trends Pharmacol Sci. 2010 Apr;31(4):144-52. doi: 10.1016/j.tips.2009.12.004. Epub 2010 Feb 1.

PMID:
20117847
18.

Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Sanacora G, Treccani G, Popoli M.

Neuropharmacology. 2012 Jan;62(1):63-77. doi: 10.1016/j.neuropharm.2011.07.036. Epub 2011 Aug 3. Review.

19.

The GABA shunt: an attractive and potential therapeutic target in the treatment of epileptic disorders.

Yogeeswari P, Sriram D, Vaigundaragavendran J.

Curr Drug Metab. 2005 Apr;6(2):127-39. Review.

PMID:
15853764
20.

Are compounds acting at metabotropic glutamate receptors the answer to treating depression?

Palucha A.

Expert Opin Investig Drugs. 2006 Dec;15(12):1545-53. Review.

PMID:
17107280

Supplemental Content

Support Center